ReviewThe Yale journal of biology and medicine2011
Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'.
Review in The Yale journal of biology and medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Nano-Radiopharmaceuticals in Colon Cancer: Current Applications, Challenges, and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- SPECT/CT imaging of EGFR-positive head and neck squamous cell carcinoma patient-derived xenografts withEJNMMI radiopharmacy and chemistry · 2024Article
- Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.Frontiers in immunology · 2024Review
- Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.Theranostics · 2022Review
- Formulation and clinical translation of [RSC medicinal chemistry · 2021Article
- Article
- Progress in biopharmaceutical development.Biotechnology and applied biochemistry · 2018Review
- Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.European journal of nuclear medicine and molecular imaging · 2017Review
- Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Expert opinion on biological therapy · 2016Review
- Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response.Journal of cancer science & therapy · 2015Article
- In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles.Molecular imaging and biology · 2014Article
- Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014Article
- Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma.Therapeutic advances in hematology · 2014Review
- Radiolabeling strategies for tumor-targeting proteinaceous drugs.Molecules (Basel, Switzerland) · 2014Review
- Target Therapy in Hematological Malignances: New Monoclonal Antibodies.International scholarly research notices · 2014Review
- The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer.European journal of medical research · 2013Article
- Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases.Molecules (Basel, Switzerland) · 2013Review
- Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine.Journal of oncology · 2013Article
- Pharmacokinetic considerations for antibody drug conjugates.Pharmaceutical research · 2012Review
- Is radioimmunotherapy a 'magic bullet'?The Korean journal of hematology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioimmunotherapy (RIT) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B-cell non-Hodgkin´s lymphoma. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Hodgkin's lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation of RIT. The predominant complication of RIT is hematological toxicity that is usually manageable. There are ongoing trials to further define the expanding role of RIT as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role of RIT in treatment of non-Hodgkin's lymphoma, which is of established clinical utility and FDA approved. The mechanism of RIT, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
Indexed as
Identifiers
22180677PMC3238311W98238742What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.